Now online on #TAMO 👇️ Consensus recommendations for the management of Dato-DXd-associated adverse events In particular: 👁️ ocular toxicity 🫁 interstitial lung disease and pneumonitis 🍴 oral mucositis management and recommendations - buff.ly/LyOtiZt

Consensus recommendations for the management of Dato-DXd-associated adverse events in patients with advanced/metastatic NSCLC: insights from a multiregional steering committee - William Nassib William, Daniel Brungs, Emerson Fernandes de Sousa e Castro, Herbert H. Loong, James C. H. Yang, Kyung-Ah Park, Mehmet ali Nahit Sendur, Mohsen Mokhtar, Se-Hoon Lee, Senthil Rajappa, Stephanie P. L. Saw, Tsung-Ying Yang, Tuncay Göksel, 2026

Datopotamab deruxtecan (Dato-DXd) is a novel antibody-drug conjugate currently under investigation in clinical trials of various solid tumors. In this manuscrip...

journals.sagepub.com

🚨 Call for Papers! Submit to our special collection on bladder-sparing strategies in urothelial carcinoma 🧪 Novel therapies & combinations 📈 Emerging clinical insights 👉 Learn more & submit: buff.ly/x5jNw3U #CallForPapers #Oncology #CancerResearch

📣 Call for Papers We’re inviting submissions for our special collection: Clinical Trials Driving Innovation in Oncology Share your latest research and help shape the future of cancer care. 🔗 Learn more & submit: buff.ly/bioqZyF #Oncology #ClinicalTrials #AcademicPublishing #CallForPapers

📰 Do antibody–drug conjugates outperform docetaxel in previously treated advanced NSCLC? This systematic review & meta-analysis of RCTs explores efficacy and safety outcomes 👇 🔗 buff.ly/YzcZqhm #Oncology #LungCancer #NSCLC #CancerResearch #ClinicalTrials

🧪 Can a simple blood-based marker help predict treatment response in ESCC? This multicenter real-world study evaluates PIV in patients receiving neoadjuvant chemotherapy combined with anti–PD-1 therapy. 🔗 buff.ly/XjR59n1 #Oncology #Biomarkers #Immunotherapy

📘 Evidence for post-progression strategies in HER2+ metastatic #BreastCancer with brain metastases remains limited. This multicenter real-world study adds insight into pyrotinib treatment beyond progression and rechallenge: buff.ly/0sbfEcd #ClinicalResearch

🆕 Can genotype-guided dosing improve outcomes in metastatic #colorectalcancer? This phase II RCT explores regorafenib + FOLFIRI with UGT1A1-guided irinotecan escalation👇 🔗 journals.sagepub.com/doi/full/10.... #Oncology #ClinicalTrials #PrecisionMedicine

📢Can a simple blood-based marker predict outcomes to #immunotherapy? This study explores how the pretreatment NLR relates to immune checkpoint inhibitor response in advanced #NSCLC with liver metastases. 🔗 Read more: buff.ly/osVDOYL #LungCancer #CancerResearch #Biomarkers

Cytokine release syndrome (CRS) isn’t just a challenge in hematologic cancers -it’s increasingly relevant in solid tumours. This review dives into mechanism-driven strategies for prevention and management. 📖 buff.ly/ZDar0oT #Oncology #Immunotherapy #CancerResearch #ClinicalInsights

🧬 Review on Solitary Fibrous Tumour explores histology, behaviour, risk assessment & treatment strategies. Stay ahead with the latest insights 👇 🔗 buff.ly/Yzeri1f #Oncology #Pathology #CancerResearch

📊 IF 4.1 for Therapeutic Advances in Medical Oncology 🎉 Consistent, high-quality research in oncology - 📚 Start reading: journals.sagepub.com/home/tam #ImpactFactor #OncologyResearch

🔬Research shows how virtual multiplex immunofluorescence can identify lymphocyte subsets that predict response to neoadjuvant therapy - advancing precision oncology. Read more: buff.ly/PvVYaEX #Oncology #CancerResearch #Immunology #PrecisionMedicine

📣 Call for Papers – Submit to our Special Collection on: Tumor Microenvironment in GI Cancers 🔬 Focus: clinically actionable biomarkers & therapeutic insights 📊 Clinical + translational research encouraged 🗓 Deadline: 15 March 2027 👉 buff.ly/dpUqDMk #CallForPapers #PrecisionOncology

🆕 Nationwide real‑world data reveal how treatment gaps are linked to survival outcomes in #HepatocellularCarcinoma, highlighting unmet needs in routine care. 🔗 buff.ly/BF3QeGz #HCC #LiverCancer #CancerOutcomes #RealWorldEvidence

How do physicians approach treatment decisions for young patients with HR+, HER2‑ early #breastcancer? This Latin American survey provides insights into real‑world clinical practice. 🔗 buff.ly/isnY3xJ #BreastCancer #YoungPatients #ClinicalPractice #Oncology

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

🆕 This study explores afatinib dose optimization to improve outcomes while reducing toxicities in advanced EGFR‑mutated NSCLC patients in Vietnam. 🔗 buff.ly/XucLdR2 #LungCancer #NSCLC #EGFR #TargetedTherapy #Oncology

📢 This phase Ib/II study investigates the addition of neoadjuvant neratinib to standard therapy in patients with inflammatory #breastcancer, including those with HER2+ and HR+/HER2‑ disease across stage III and IV settings. 👉 Read the full article: buff.ly/bFwUuVM #InflammatoryBreastCancer #HER2 #

🆕 A multicenter phase II randomized trial evaluates Endostar + concurrent chemoradiotherapy in locally advanced cervical cancer. 🔗 Read the full article: buff.ly/mQhOTsg #CervicalCancer #OncologyResearch #ClinicalTrials #Radiotherapy

🚨 Call for Papers The KRAS era is here - now we need strategies to anticipate & overcome resistance in pancreatic cancer. Submit by Mar 1, 2027: KRAS pathways, combos, resistance mechanisms, new targets & models. 🔗 buff.ly/eMwzb2N #PDAC #KRAS #TargetedTherapy #CancerResearch

A large French multicenter cohort study examines how age influences clinical characteristics, treatment patterns, and outcomes in #BiliaryTractCancer, highlighting differences in unresectable disease and comparable survival after resection. buff.ly/6PIVm3G #Cholangiocarcinoma #GeriatricOncology

📣 Call for Papers A Collection in Ther Adv Med Oncol focuses on #ADCs in gynecologic cancers, including ovarian, endometrial, and cervical malignancies. We welcome clinically relevant research and reviews. 🗓️ Deadline: 26 Feb 2027 buff.ly/30K8r13 #GynecologicOncology #CancerResearch #OpenCall

A narrative review summarises recent advances and key trials of radionuclide therapies, including ²²³Ra, ¹⁷⁷Lu‑labelled agents, and emerging α‑emitters, in metastatic castration‑resistant #ProstateCancer. Ther Adv Med Oncol buff.ly/XQWUg2J #RadionuclideTherapy

Current status of radionuclide therapies in metastatic castration-resistant prostate cancer - Xin Fei, Rui-Da Huang, Xuan Zhou, Shi-Jie Ye, Nan Nan, Ke-Jie Wang, Qi Ma, 2025

The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains a huge challenge. Newer radionuclides, such as 223Ra, 177Lu, 225Ac, etc., have ...

journals.sagepub.com

We invites submissions to the Collection “Advances in Acute Myeloid Leukemia (AML) Therapy in the Precision Medicine Era.” Submission deadline: 19 Feb 2027 buff.ly/xsqkygl #AML #PrecisionOncology #HematologicMalignancies #MRD

A study across Brazil, Mexico, and Peru examines how fertility concerns influence acceptance of (neo)adjuvant chemotherapy among young women with early-stage #BreastCancer, highlighting gaps in awareness and access to fertility preservation. buff.ly/W1gWits #OncoFertility #CancerCare #LatinAmerica

📣 If you will be at #ESTRO26 please connect with my team member Applonia! She is alsI Editor of the journal Technology in Cancer Research & Treatment which has a significant focus on radiation oncology research. #oncosky #oncology #radiotherapy #ESTRO2026

Applonia Rose@apploniarose.bsky.social · 3mo ago

I'll be attending #ESTRO2026 next week!! A great chance to engage with the radiation oncology community and explore emerging directions. I'm representing TCRT @tcrtcancer.bsky.social and particularly keen to connect with our board members and authors. Happy to connect if you’ll be there.

📣 Call for Papers - Volume 2 Following the success of Volume 1, Ther Adv Med Oncol launches Volume 2 of this Collection on #ADC in #BreastCancer, focusing on new standards, emerging challenges, and future directions. Deadline: 29 Jan 2027 journals.sagepub.com/topic/collec... #MedicalOncology

Resistance to second‑generation AR pathway inhibitors remains a key challenge in #ProstateCancer. This review explores mechanisms of resistance and emerging third‑generation strategies, including AR degraders and steroid biosynthesis inhibitors. buff.ly/dDwk7Tz #AndrogenReceptor #PrecisionOncology

Call for papers: a new collection in Ther Adv Med Oncol focuses on immunotherapy for T‑cell malignancies, spanning checkpoint inhibition, ADCs, bispecifics, cellular therapies, biomarkers, and resistance mechanisms. buff.ly/y2kbSVy #HematologicMalignancies #Immunotherapy #TCellLymphoma

Genomic profiling is reshaping research strategies in cervical, vulvar & vaginal cancers. This review summarises molecular features across tumour types and examines emerging targeted and combination approaches, including #ADC. buff.ly/EP7cYS5 #GynOnc #PrecisionOncology #CancerGenomics

A new Collection in Ther Adv Med Oncol examines how biomarker‑driven strategies are shaping lung cancer care across the disease continuum. Deadline: 29 Jan 2027 buff.ly/RrkerAu #LungCancer #PrecisionOncology #Biomarkers #MedicalOncology